Sean Smith
Analyst · Needham and Company
Thanks, Deno and good morning, everyone. I'll provide a brief analysis of our financial results for the third quarter of fiscal year 2012, review our balance sheet and cash flow and then provide our outlook going forward. Please refer to Slide 4 for our GAAP to non-GAAP net income reconciliation as we review the third quarter.
Slide 5, 6 and 7 show our sequential quarterly and year-to-date IC and FPD revenue performance. As Deno mentioned, third quarter revenue decreased by about 1% sequentially to $116.6 million due to a slowdown during the last few weeks of the quarter principally in high-end IC markets principally related to memory and, to a lesser extent, reduced demand for FPD photomask. Revenues for IC and FPD photomask were $90.3 million and $26.3 million respectively for the third quarter.
Breaking out sales geographically, 61% of total sales were from Asia, 29% from North America and 10% from Europe. High-end global IC sales of $27.4 million or 30% of total IC sales for the quarter. This represents a sequential decrease of approximately 12%. As Deno mentioned, while high-end sales were down sequentially, mainstream sales rebounded with a sequential increase of $5.1 million or 9%.
Advanced FPD sales were $17.3 million or 66% of total sales. As a reminder, high-end IC revenues consist of revenue derived from SEMI design at and below 45 nanometers and high-end FPD revenues consist of revenue at and above G8, as well as AMOLED-based products.
Now let's continue through the income statement. Gross margin for third quarter was 27.7%, up 230 basis points sequentially even on a decreased sales. The improved margin related to improved manufacturing efficiencies, principally labor and materials, coupled with certain manufacturing expenses classified as R&D as a result of increased development and qualification activity at advanced nodes. The 27.7% margin is actually higher than our Q2 2011 margin when we had revenues nearly 10% higher at $133 million.
Selling, general and administrative expenses for the third quarter were $11.8 million, down sequentially by approximately $400,000 or 3% due principally to reduce labor. R&D expenses, which consists principally of continued development for our global advanced process technologies, were $5.2 million or up $900,000 sequentially as a result of the increased process development quals at advanced nodes during the quarter. It is important to note that we should begin benefiting from these advanced quals in calendar 2013. Noncash stock comp for the quarter was approximately $900,000.
Please turn to Slide 8. During the quarter, we generated operating income of $15.3 million or 13.1% of sales. Sequentially, operating income rose $2.1 million or 16% despite the $8,000 reduction in sales for the quarter as a result of the previously mentioned manufacturing expenses. EBITDA, as defined in our credit agreement for the quarter, was approximately $38 million. This equates to $145 million on a trailing 12-month basis. Also on a trailing 12-month basis, free cash flow was $55 million. EBITDA of $145 million less non-financed CapEx of $90 million. Other income and expense for the third quarter was expense of $800,000, down $200,000 sequentially due principally to favorable foreign currency exchange.
During the third quarter, we recorded tax provision of $3.3 million, which was within our guided range. GAAP net income and non-GAAP net income was approximately $11 million, and EPS per diluted share was $0.16, which was the mid-point of our original guidance of $0.14 to $0.18 per share. At the end of the third quarter, we had 1,265 full-time employees. This equates to revenue per employee of $369,000 on an annualized basis. Year-to-date, employee headcount is down approximately 6.3%.
Now turning to the balance sheet. Cash and cash equivalents amount to $197 million and our net cash, which is cash less debt, was $19 million or up $7 million sequentially. Our working capital at the end of the quarter was $212 million, which is down slightly from the end of Q2 at $221 million. Accounts payable and accrued liability at July 29 amounted to $91 million, and at the end of the quarter, we had approximately $5 million of CapEx accrued for.
Please turn to Slide 9 as we review our capitalization. Total debt at July 29 was $178 million. The principal components of outstanding debt include: $22 million of 5.5% senior unsecured convertible notes, which are due October 2014; $115 million, 3.25% senior unsecured notes, which are due in April of 2016; approximately $16 million for our capital lease obligation; $24 million, 2.5% 5-year term loan relates to the nanoFab building; and approximately $1 million related to an obligation with a customer who co-funded a tool purchase. At the end of the Q -- quarter, we do not have any outstanding borrowings on our $30 million revolving credit agreement, which matures April of 2015.
Taking a look at our cash flows. Cash provided by operations for the third quarter of 2012 was approximately $45 million. Depreciation and amortization was $20.9 million for the quarter and year-to-date cash provided by operations was $108 million. Cash flow used in investing activities during Q3 amounted to $32 million. It includes $24 million for cash payments for capital expenditures and $7 million from increased investments in our joint venture. Net cash used by financing activities during the quarter, amounted to $5 million and includes $4 million related to the repurchase of PSMC shares.
As we look ahead, please turn to Slide 10. We expect our CapEx needs on a cash basis excluding the $25 million for the financed portion of the nanoFab building in 2012 to be in the range of $80 million to $85 million. Our initial outlook for CapEx in 2013 is projected to be in the $70 million to $90 million range. However, we do have the flexibility to accelerate or decelerate our spend depending upon market conditions. Our 2012 and 2013 investments will principally be geared toward high-end, leading edge products for IC and FPD applications in the U.S., in Taiwan and in Korea. This significant high-end revenue increases the market share gains we have seen in 2011, thus far in 2012 have certainly validated our high-end strategy. Our visibility, as always, continues to be limited as our backlog is 1 to 2 weeks. For Q4, we do expect to experience some typical seasonality related to the U.S. and European summer holiday vacation season. We also expect to continue to see a somewhat muted market for certain high-end IC orders as we did during the month of July. So taking this all into consideration, we are projecting revenue for the fourth quarter to be in the range of $114 million to $118 million.
Taking a look at taxes. For the fourth quarter, we're estimating tax expense in the range of $3 million to $4 million. And as a result, based upon our current operating model, we estimate that EPS for the fourth quarter of fiscal 2012 to be in the range of $0.14 to $0.17 per diluted share.
Please turn to Slide 11. In summary, I'll leave you with a few key thoughts. First, we continue to generate free cash flow and expect to do so in the near term. Second, we are confident that our business model and our ability to weather any short-term softness in the market while continuing to grow our market share at the high end. In Q3, we're able to report improved gross and operating margins on sequentially -- on a sequential basis on lower revenues. We see continued opportunities on our customer business and node migration plans, and we have a strong financial position and excellent technology to capitalize on those plans. And finally, we expect to continue to build on the momentum that we've established over the past few years as a leader in advanced photomask technology. Although our visibility is limited, as always we plan to match our operating infrastructure to the market environment. Now, I'd like to turn the call over to the operator for questions and answers.